Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 1 hour ago
Cardiac medtech HeartBeam drops CEO in restructuring aimed at global ECG platform push
about 1 hour ago
HeartBeam, the maker of a cable-free ECG system, moved CEO Robert Eno...
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
about 2 hours ago
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass...
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
about 2 hours ago
Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing...
The deal before the deal
about 3 hours ago
Before a biotech deal gets signed, companies are already being tested by...
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
about 3 hours ago
Moderna has unveiled its first in vivo CAR-T program. Building on other...
Chutes & Ladders—EMD Serono taps in new commercial strategy head
about 4 hours ago
EMD Serono, Merck KGaA’s North American healthcare arm, has promoted from within...
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery
about 7 hours ago
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered...
Puerto Rico makes its case as a biotech manufacturing hub
about 13 hours ago
Puerto Rico is building on its pharma manufacturing legacy to attract advanced...
Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
about 15 hours ago
In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D...
BIO 2026: How a gut feeling transformed cancer treatment forever
1 day ago
Dr. Israel Lowy remembers the days when he and his oncology immunotherapy...
Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision
1 day ago
A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder prospect has hit its...
With $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platform
1 day ago
TechBio outfit Immunai is continuing its parade of Big Pharma partnerships with...